Products for Research Use Only

Pemigatinib-d6

CAT: 0804-HY-W754878Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-W754878Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Pemigatinib-d6 (INCB054828-d6) is deuterium labeled Pemigatinib. Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma[1][2][3].
CAS Number
2649492-49-7
Product Name Alternative
INCB054828-d6
UNSPSC
12352005
Target
FGFR; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Others; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
O=C1N(C2=C3C(NC(CN4CCOCC4)=C3)=NC=C2CN1C5=C(C(OC([2H])([2H])[2H])=CC(OC([2H])([2H])[2H])=C5F)F)CC
Molecular Formula
C24H21D6F2N5O4
Molecular Weight
493.54
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Arudra K, et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct;45 (10) :786-790.|[3]Roskoski R Jr, et al. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2020 Jan;151:104567.|[4]Krook MA, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019 Aug 1;5 (4) .
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Alternative Products